yellow fever virus strain 17D-204 live antigen
yellow fever virus strain 17D-204 live antigen: 7 clinical trials tracked.
yellow fever virus strain 17D-204 live antigen evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about yellow fever virus strain 17D-204 live antigen, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (7)
A Phase 3, Single Arm, Open Study to Assess the Immunogenicity and Safety of vYF in Adults Aged 18 Years and Over
Primary endpoint: Percentage of participants with seroconversion to YF virus in YF-naive participants
A Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of Age
Primary endpoint: Percentage of participants with seroconversion to YF virus after 1 dose of vYF compared to seroconversion after 1 dose of the Stamaril in YF-naive participants (9-24 months)
A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years
Primary endpoint: Number of participants with immediate adverse events
A Human Experimental Medicine Study to Assess Whether the Gut Microbiota Regulates Specific and Non-specific Immune Responses to Vaccination
Primary endpoint: Sub-study 1 BCG re-challenge
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril in Adults
Primary endpoint: Percentage of Yellow Fever-naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults
Primary endpoint: Percentage of Yellow Fever (YF)-Naive Participants Who Achieved Seroconversion 28 Days Post Dose 1
Safety, Tolerability, and Immunogenicity Dose-ranging Study of the Investigational Yellow Fever Vacine (vYF) Candidate Vaccine in Adults
Primary endpoint: Number of participants with immediate adverse events